Scientific article

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis

Published inBiology of blood and marrow transplantation, vol. 20, no. 11, p. 1841-1846
Publication date2014

To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.

Citation (ISO format)
ROBIN, Marie et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. In: Biology of blood and marrow transplantation, 2014, vol. 20, n° 11, p. 1841–1846. doi: 10.1016/j.bbmt.2014.06.011
Main files (1)
Article (Published version)
ISSN of the journal1083-8791

Technical informations

Creation05/01/2015 12:37:00 PM
First validation05/01/2015 12:37:00 PM
Update time03/14/2023 11:15:17 PM
Status update03/14/2023 11:15:15 PM
Last indexation01/16/2024 5:55:19 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack